X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (957) 957
male (634) 634
octreotide (594) 594
female (517) 517
octreotide - pharmacokinetics (449) 449
index medicus (439) 439
middle aged (386) 386
animals (382) 382
octreotide - therapeutic use (375) 375
octreotide - analogs & derivatives (366) 366
adult (355) 355
somatostatin - analogs & derivatives (298) 298
aged (292) 292
somatostatin (264) 264
rats (218) 218
radiopharmaceuticals - pharmacokinetics (215) 215
endocrinology & metabolism (213) 213
pharmacology & pharmacy (212) 212
oncology (200) 200
octreotide - administration & dosage (199) 199
tissue distribution (194) 194
receptors, somatostatin - metabolism (193) 193
radiology, nuclear medicine & medical imaging (174) 174
medicine & public health (165) 165
neuroendocrine tumors (158) 158
radionuclide imaging (157) 157
acromegaly - drug therapy (153) 153
somatostatin - therapeutic use (153) 153
octreotide - pharmacology (150) 150
treatment outcome (150) 150
tumors (147) 147
therapy (131) 131
mice (126) 126
pharmacokinetics (125) 125
octreotide - adverse effects (124) 124
acromegaly (112) 112
peptides (105) 105
somatostatin - pharmacokinetics (103) 103
gastroenterology & hepatology (100) 100
management (97) 97
somatostatin analog (97) 97
radiopharmaceuticals - therapeutic use (95) 95
somatostatin analogs (94) 94
cancer (93) 93
somatostatin - administration & dosage (90) 90
pentetic acid - analogs & derivatives (87) 87
sms 201-995 (86) 86
radionuclide therapy (84) 84
organometallic compounds - pharmacokinetics (83) 83
octreotide - chemistry (82) 82
neuroendocrine tumors - diagnostic imaging (81) 81
efficacy (80) 80
delayed-action preparations (76) 76
pentetic acid - pharmacokinetics (75) 75
time factors (75) 75
indium radioisotopes - pharmacokinetics (74) 74
lanreotide (74) 74
aged, 80 and over (73) 73
peptides, cyclic - therapeutic use (73) 73
cell line, tumor (72) 72
scintigraphy (70) 70
surgery (70) 70
neuroendocrine tumors - metabolism (69) 69
nuclear medicine (69) 69
adolescent (66) 66
imaging / radiology (66) 66
neuroendocrine tumors - radiotherapy (66) 66
diagnosis (65) 65
growth-hormone (65) 65
somatostatin receptors (65) 65
care and treatment (64) 64
secretion (63) 63
kidney - metabolism (62) 62
analysis (61) 61
antineoplastic agents - therapeutic use (60) 60
antineoplastic agents, hormonal - therapeutic use (60) 60
in-vitro (60) 60
injections, subcutaneous (60) 60
somatostatin - pharmacology (60) 60
cardiology (59) 59
insulin (57) 57
receptors, somatostatin - analysis (57) 57
dose-response relationship, drug (55) 55
health aspects (55) 55
indium radioisotopes (55) 55
pancreatic neoplasms - metabolism (55) 55
somatostatin - adverse effects (55) 55
half-life (54) 54
mice, nude (53) 53
orthopedics (53) 53
radiotherapy (53) 53
receptors (53) 53
dosimetry (52) 52
expression (52) 52
medicine (52) 52
in-vivo (51) 51
insulin-like growth factor i - metabolism (51) 51
metabolic clearance rate (51) 51
pancreatic neoplasms - diagnostic imaging (51) 51
rats, wistar (51) 51
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1346) 1346
German (8) 8
French (4) 4
Spanish (4) 4
Chinese (2) 2
Japanese (2) 2
Polish (2) 2
Russian (2) 2
Italian (1) 1
Korean (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Endocrine-Related Cancer, ISSN 1351-0088, 03/2010, Volume 17, Issue 1, pp. R53 - R73
Somatostatin receptor imaging (SRI) with [ 111 In-DTPA 0 ]octreotide has proven its role in the diagnosis and staging of gastroenteropancreatic neuroendocrine... 
LUNG-CANCER | POSITRON-EMISSION-TOMOGRAPHY | ONCOLOGY-GROUP | ISLET-CELL CARCINOMA | ONCOLOGY | PHASE-I TRIAL | RADIONUCLIDE THERAPY | ENDOCRINOLOGY & METABOLISM | LOW-GRADE | MEDULLARY-THYROID CARCINOMA | QUALITY-OF-LIFE | OCTREOTIDE SCINTIGRAPHY | Humans | Digestive System Neoplasms - radiotherapy | Antineoplastic Agents - therapeutic use | Yttrium Radioisotopes - pharmacokinetics | Octreotide - pharmacokinetics | Digestive System Neoplasms - drug therapy | Gallium Radioisotopes - therapeutic use | Digestive System Neoplasms - diagnostic imaging | Neuroendocrine Tumors - diagnostic imaging | Receptors, Somatostatin - analysis | Organometallic Compounds - therapeutic use | Yttrium Radioisotopes - therapeutic use | Somatostatin - analogs & derivatives | Radiopharmaceuticals - pharmacokinetics | Octreotide - analogs & derivatives | Organometallic Compounds - pharmacokinetics | Treatment Outcome | Clinical Trials as Topic | Combined Modality Therapy | Indium Radioisotopes - pharmacokinetics | Positron-Emission Tomography - methods | Octreotide - therapeutic use | Somatostatin - pharmacokinetics | Peptides, Cyclic - pharmacokinetics | Neuroendocrine Tumors - radiotherapy | Animals | Organotechnetium Compounds - pharmacokinetics | Positron-Emission Tomography - standards | Receptors, Somatostatin - drug effects | Gallium Radioisotopes - pharmacokinetics | Neuroendocrine Tumors - drug therapy | Peptides, Cyclic - therapeutic use | Quality of Life | Indium Radioisotopes - therapeutic use | Somatostatin - therapeutic use | Radiopharmaceuticals - therapeutic use
Journal Article
European Journal of Nuclear Medicine and Molecular Imaging, ISSN 1619-7070, 4/2003, Volume 30, Issue 4, pp. 510 - 518
Journal Article
Journal Article
Journal Article
Journal Article
Molecular Pharmaceutics, ISSN 1543-8384, 10/2011, Volume 8, Issue 5, pp. 1641 - 1651
A new conjugate, octreotide–polyethylene glycol(100) monostearate (OPMS), was developed for the enhancement of targeting delivery of hydroxycamptothecine... 
somatostatin receptor | nanostructured lipid carrier | polyethylene glycol monostearate | octreotide | SOMATOSTATIN ANALOGS | MOLECULAR-WEIGHT | DRUG-DELIVERY | ADSORPTION-KINETICS | LIPOPROTEIN-LIPASE | NANOPARTICLES | PLASMA-PROTEINS | POLY(ETHYLENE GLYCOL) | FIXED AQUEOUS LAYER | PHARMACOLOGY & PHARMACY | PARTICLE-SIZE | Camptothecin - chemistry | Humans | Half-Life | Male | Polyethylene Glycols - chemistry | Antineoplastic Agents - administration & dosage | Neoplasm Proteins - metabolism | Drug Carriers - chemistry | Antineoplastic Agents - metabolism | Lipids - chemistry | Biological Transport | Chemical Phenomena | Camptothecin - administration & dosage | Liver Neoplasms - pathology | Nanostructures - adverse effects | Antineoplastic Agents - pharmacokinetics | Receptors, Somatostatin - metabolism | Camptothecin - analogs & derivatives | Camptothecin - pharmacokinetics | Nanostructures - ultrastructure | Camptothecin - metabolism | Drug Carriers - metabolism | Lipids - adverse effects | Rats | Antineoplastic Agents - chemistry | Rats, Sprague-Dawley | Animals | Carcinoma, Hepatocellular - pathology | Liver Neoplasms - metabolism | Cell Line, Tumor | Nanostructures - chemistry | Octreotide - chemistry | Ligands | Drug Carriers - pharmacokinetics | Delayed-Action Preparations | Carcinoma, Hepatocellular - metabolism
Journal Article
Pharmaceutical Research, ISSN 0724-8741, 10/2012, Volume 29, Issue 10, pp. 2902 - 2911
Journal Article
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 05/2016, Volume 230, pp. 45 - 56
Journal Article
Journal Article
European Journal of Nuclear Medicine, ISSN 0340-6997, 9/2001, Volume 28, Issue 9, pp. 1319 - 1325
Journal Article